Alphabet: Analyst Consensus Points To Q2 Revenues Of $69.95 Billion

Alphabet (NASDAQ: GOOGL) will be reporting its second quarter financial results on July 26th after market close. Analysts have a consensus $153.83 12-month price target on the company, via a total of 50 analysts, with 15 analysts having strong buy ratings. 32 analysts meanwhile have buy ratings and three analysts have hold ratings. The street high comes from Elazar Advisors with a $226.67 price target, and the lowest target sits at $118.

31 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 31 analysts is $69.95 billion; this number has been slightly revised downwards since the start of the year. The highest revenue estimate is $72.1 billion, while the lowest is $66.85 billion.

Onto EBITDA estimates, there are currently 25 analysts who have second-quarter EBITDA estimates. The mean is currently $28.55 billion. The estimate has been revised lower since the start of the year. Street high is a $30.68 billion EBITDA estimate, and the lowest is $26.9 billion.

Analysts estimate that quarterly earnings per share will come in at $1.29, slightly down from the $1.34 estimate at the start of the year. The street high estimate is $1.54 and the lowest estimate is $1.12 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The $30,000 Gold Case Just Got Stronger | Simon Marcotte

Why Silver’s Move Is ‘Scary’ to Some Miners | Frank Basa

Are Commodities Entering a Generational Cycle? | Terry Lynch

Recommended

Ottawa Backs First Phosphate Battery Grade Validation Push With $16.7M Boost

First Majestic Drills 3.43 g/t Gold Over 24.4 Metres At Jerritt Canyon

Related News

Cresco Labs: Stifel Slashes Price Target From $30 To $8 Following Poor Q4 Results

On March 23rd, Cresco Labs (CSE: CL) announced its fourth-quarter financial results, which disappointed many...

Friday, March 25, 2022, 03:39:00 PM

Well Health: Canaccord Reiterates Ratings Following Recent Acquisition

Last week WELL Health Technologies (TSX: WELL) announced their latest acquisition, a majority stake in...

Friday, September 10, 2021, 03:29:00 PM

Aphria: Canaccord Downgrades Company To Hold From Speculative Buy

Earlier this week, it was announced that Aphria Inc (TSX: APHA) (NASDAQ: APHA) and Tilray...

Friday, December 18, 2020, 12:05:00 PM

NG Energy: Canaccord Initiates Coverage With $1.40 Price Target

Last week Canaccord Genuity Capital Markets’ initiated coverage on NG Energy (TSXV: GASX) with a...

Friday, July 22, 2022, 12:37:00 PM

WELL Health: Canaccord Increases Price Target To $8.50 Following Bought Deal

This morning Canaccord Genuity raised their 12-month price target on WELL Health Technologies (TSX: WELL)...

Friday, October 23, 2020, 01:37:00 PM